Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.83 HKD | +0.74% | -2.15% | +2.25% |
Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.25% | 601M | |
+42.79% | 739B | |
+32.34% | 598B | |
-5.57% | 353B | |
+17.75% | 318B | |
+3.76% | 285B | |
+16.47% | 240B | |
+9.26% | 210B | |
-5.07% | 206B | |
+6.74% | 164B |
- Stock Market
- Equities
- 1477 Stock
- News Ocumension Therapeutics
- Ocumension Therapeutics’ Loss for 2023 Narrows; Shares Down 4%